Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jan;21(1):53–61. doi: 10.1111/j.1365-2125.1986.tb02822.x

Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.

J N Harvey, D P Worth, J Brown, M R Lee
PMCID: PMC1400809  PMID: 2868748

Abstract

A series of studies were undertaken to assess the effect of oral fenoldopam, a specific DA1 dopamine receptor agonist on blood pressure and renal function in patients with mild essential hypertension. Six patients with essential hypertension were entered into a dose-ranging study and received either placebo, 25, 50 or 100 mg fenoldopam. A significant, dose-related reduction in diastolic blood pressure, and increase in heart rate was demonstrated (both P less than 0.05), maximal at 45 min to 1 h. Fenoldopam increased plasma renin activity. In a double-blind study, seven patients received a single dose of fenoldopam 100 mg or placebo. Fenoldopam produced a significant fall in systolic (P less than 0.05) and diastolic (P less than 0.01) blood pressure and renal vascular resistance (P less than 0.01). Urine flow rate (P less than 0.05), sodium excretion (P less than 0.01), plasma renin activity (P less than 0.05) and plasma aldosterone (P less than 0.05) increased. Five patients underwent measurement of the above parameters following a single dose of fenoldopam 100 mg with a repeat of these measurements after they had taken fenoldopam 100 mg four times daily for 1 month. The acute response of blood pressure to the single dose appeared unchanged but tachyphylaxis was evident in the responses of heart rate, plasma renin activity and plasma aldosterone.

Full text

PDF
53

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman D. M., Blumberg A. L., McCafferty J. P., Sherman S. S., Weinstock J., Kaiser C., Berkowitz B. Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526. Fed Proc. 1983 Feb;42(2):186–190. [PubMed] [Google Scholar]
  2. Bello-Reuss E., Higashi Y., Kaneda Y. Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule. Am J Physiol. 1982 Jun;242(6):F634–F640. doi: 10.1152/ajprenal.1982.242.6.F634. [DOI] [PubMed] [Google Scholar]
  3. Britton K. E. Essential hypertension: a disorder of cortical nephron control. Lancet. 1981 Oct 24;2(8252):900–902. doi: 10.1016/s0140-6736(81)91393-3. [DOI] [PubMed] [Google Scholar]
  4. Carey R. M., Stote R. M., Dubb J. W., Townsend L. H., Rose C. E., Jr, Kaiser D. L. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest. 1984 Dec;74(6):2198–2207. doi: 10.1172/JCI111646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. EBLE J. N. A PROPOSED MECHANISM FOR THE DEPRESSOR EFFECT OF DOPAMINE IN THE ANESTHETIZED DOG. J Pharmacol Exp Ther. 1964 Jul;145:64–70. [PubMed] [Google Scholar]
  6. Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972 Mar;24(1):1–29. [PubMed] [Google Scholar]
  7. Goldberg L. I., Kohli J. D. Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol. 1979;3(6):447–456. [PubMed] [Google Scholar]
  8. Goldring W., Chasis H., Ranges H. A., Smith H. W. EFFECTIVE RENAL BLOOD FLOW IN SUBJECTS WITH ESSENTIAL HYPERTENSION. J Clin Invest. 1941 Nov;20(6):637–653. doi: 10.1172/JCI101257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  10. Hahn R. A., Wardell J. R., Jr, Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther. 1982 Nov;223(2):305–313. [PubMed] [Google Scholar]
  11. Hardaker W. T., Jr, Wechsler A. S. Redistribution of renal intracortical blood flow during dopamine infusion in dogs. Circ Res. 1973 Oct;33(4):437–444. doi: 10.1161/01.res.33.4.437. [DOI] [PubMed] [Google Scholar]
  12. Harries J. D., Mildenberger R. R., Malowany A. S., Drummond K. N. A computerized cummulative integral method for the precise measurement of the glomerular filtration rate. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1148–1155. doi: 10.3181/00379727-140-36630. [DOI] [PubMed] [Google Scholar]
  13. Harvey J. N., Casson I. F., Clayden A. D., Cope G. F., Perkins C. M., Lee M. R. A paradoxical fall in urine dopamine output when patients with essential hypertension are given added dietary salt. Clin Sci (Lond) 1984 Jul;67(1):83–88. doi: 10.1042/cs0670083. [DOI] [PubMed] [Google Scholar]
  14. Harvey J. N., Worth D. P., Brown J., Lee M. R. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol. 1985 Jan;19(1):21–27. doi: 10.1111/j.1365-2125.1985.tb02608.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hollenberg N. K., Borucki L. J., Adams D. F. The renal vasculature in early essential hypertension: evidence for a pathogenetic role. Medicine (Baltimore) 1978 Mar;57(2):167–178. doi: 10.1097/00005792-197803000-00004. [DOI] [PubMed] [Google Scholar]
  16. MCDONALD R. H., Jr, GOLDBERG L. I., MCNAY J. L., TUTTLE E. P., Jr EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW. J Clin Invest. 1964 Jun;43:1116–1124. doi: 10.1172/JCI104996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stote R. M., Dubb J. W., Familiar R. G., Erb B. B., Alexander F. A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther. 1983 Sep;34(3):309–315. doi: 10.1038/clpt.1983.173. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES